TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from BerGenBio ASA ( (BRRGF) ) is now available.
Oncoinvent ASA has announced a fully underwritten rights issue to raise NOK 130 million, with tradable subscription rights allocated to primary insiders and their close associates. This financial move is expected to support the ongoing development and trials of their innovative cancer treatment, Radspherin®, potentially strengthening their market position and offering new hope for patients with limited treatment options.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their leading product, Radspherin®, targets micro-metastases in the peritoneum post-surgery using radium-224, and is currently undergoing clinical trials in the US and Europe for ovarian cancer.
Average Trading Volume: 217,315
Current Market Cap: NOK266.7M
See more data about BRRGF stock on TipRanks’ Stock Analysis page.